S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
NASDAQ:RXRX

Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis

$7.40
-0.07 (-0.94%)
(As of 04/18/2024 ET)
Today's Range
$7.27
$7.58
50-Day Range
$7.40
$15.52
52-Week Range
$4.54
$16.75
Volume
2.86 million shs
Average Volume
6.63 million shs
Market Capitalization
$1.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.75

Recursion Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
72.3% Upside
$12.75 Price Target
Short Interest
Healthy
27.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Recursion Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$3.83 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.63) to ($1.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.50 out of 5 stars

Medical Sector

448th out of 918 stocks

Biological Products, Except Diagnostic Industry

64th out of 147 stocks

RXRX stock logo

About Recursion Pharmaceuticals Stock (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology and data science company based in Salt Lake City, Utah. Founded in 2013, the company's vision is to revolutionize drug discovery by integrating cutting-edge technologies across biology, chemistry, automation, data science, and engineering. Recursion's innovative approach focuses on using human cell models of diseases, capturing microscopic images to build extensive biological datasets, and employing advanced computational techniques, including artificial intelligence, to decode biology and identify disease-associated patterns.

Recursion Pharmaceuticals was incorporated in 2013 with the fundamental goal of industrializing drug discovery to accelerate the pace of identifying potential treatments for a wide range of diseases. The company aims to leverage technological innovations and data-driven insights to decode the complexities of cellular biology. Recursion aspires to transform the drug development landscape by combining AI with biological research and improving patient outcomes.

The company's key product offerings are centered around an array of novel drug candidates targeting various diseases. REC-994, currently in Phase 2 clinical trials, is being developed to treat cerebral cavernous malformation (CCM), a genetic disorder affecting the brain's blood vessels. REC-2282 is another promising candidate in Phase 2/3 clinical trials, intended to treat neurofibromatosis type 2. REC-4881, REC-3964, and a second compound with the same name, REC-4881, are also in various clinical trials for treating familial adenomatous polyposis, Clostridioides infection, and certain cancers. In addition to these clinical-stage products, Recursion Pharmaceuticals has preclinical-stage candidates, including RBM39 for HR-proficient ovarian cancer, REC-64151 targeting immune checkpoint resistance, and Anti-PD-(L)1, a small molecule to enhance sensitivity to immune checkpoint inhibitors in certain cancers.

Recursion's target market primarily comprises patients and healthcare providers seeking innovative and effective treatments for various diseases. The company's focus on rare diseases, neurological disorders, and cancer demonstrates its commitment to addressing critical unmet medical needs. Key customers for Recursion Pharmaceuticals include healthcare organizations, research institutions, and biotechnology companies collaborating in the pursuit of novel therapies.

The leadership team at Recursion Pharmaceuticals is driving the company's vision forward. Dr. Christopher C. Gibson, Ph.D., the Co-Founder, Chief Executive Officer, and Director, is a visionary leader with a deep understanding of the intersection between biology and AI. His strategic guidance has been instrumental in shaping Recursion's path to success. Ms. Tina Marriott Larson, the Chief Operation Officer and President, brings a wealth of operational expertise and a strong track record in scaling biotech ventures. Her leadership has facilitated efficient operations and resource allocation.

Over the past few years, Recursion Pharmaceuticals has shown significant revenue growth. Recently the company reported revenue representing an impressive year-over-year change of more than 100%. This surge in revenue signals strong market traction for the company's drug candidates and validates its innovative drug discovery approach. Key earnings metrics have also been favorable despite the negative value; the net profit margin and earnings per share have shown improvements. The company's financial performance reflects the significant investments made in research and development to advance its clinical and preclinical products. 

The company's debt levels are manageable, given the current financial position and potential for future growth. Recursion Pharmaceuticals has sufficient short-term assets to cover its current liabilities.

Recursion Pharmaceuticals' valuation metrics present an interesting profile compared to industry peers. While the stock has seen fluctuations, the average stock price forecast suggests that some analysts see the company as overvalued relative to its intrinsic worth. However, various factors may influence investor sentiment, including pipeline progress, clinical trial results, outside investment, and broader market dynamics. When looking at Recursion Pharmaceuticals' stock performance, we can observe fluctuations that correlate with significant events, such as clinical trial updates and regulatory developments. News related to partnerships and collaborations may also impact the stock's performance.

Recursion Pharmaceuticals operates in the biotechnology sector, specifically focusing on biological products and data science. The company has positioned itself as a leader in AI-driven drug discovery within this competitive landscape. Its innovative phenomics approach and strategic collaborations with renowned institutions and pharmaceutical giants set it apart from its peers. The company's focus on rare diseases and neurological disorders provides a strategic advantage, addressing unmet medical needs and potential market opportunities.

Recursion Pharmaceuticals has various growth opportunities due to its diverse clinical and preclinical pipeline. The expansion of clinical trials for existing candidates, successful regulatory approvals, and potential partnerships can drive future revenue growth. Additionally, the company's platform and AI-driven approach have the potential to identify new drug targets and expand therapeutic areas, presenting exciting growth prospects.

Like any biotechnology company, Recursion Pharmaceuticals faces inherent risks and challenges in drug discovery and development. Clinical trials carry uncertainties, and setbacks or failures can impact the stock price and investor sentiment. The competitive landscape poses challenges that require continued innovation and differentiation. Additionally, regulatory requirements and potential delays in approvals can influence the company's financial performance.

Recursion Pharmaceuticals employs robust risk management strategies to mitigate risks, including careful portfolio diversification across therapeutic areas, close monitoring of clinical trial progress, and prudent financial management. Collaboration with industry leaders and academic institutions strengthens the company's pipeline and risk-sharing capabilities.

RXRX Stock Price History

RXRX Stock News Headlines

Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Analyst Scoreboard: 5 Ratings For Recursion Pharmaceuticals
1 AI Growth Stock With 54% Upside Potential
Recursion Announces Plans to Open New Office in London
See More Headlines
Receive RXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/18/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:RXRX
Employees
500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.75
High Stock Price Target
$17.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+72.3%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-328,070,000.00
Net Margins
-735.99%
Pretax Margin
-745.10%

Debt

Sales & Book Value

Annual Sales
$44.58 million
Book Value
$1.98 per share

Miscellaneous

Free Float
187,816,000
Market Cap
$1.74 billion
Optionable
Optionable
Beta
0.76
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Christopher C. Gibson Ph.D. (Age 41)
    Co-Founder, CEO & Director
    Comp: $695.18k
  • Ms. Tina Marriott LarsonMs. Tina Marriott Larson (Age 49)
    COO & President
    Comp: $612.69k
  • Dr. Blake C. Borgeson Ph.D. (Age 42)
    Co-Founder & Director
    Comp: $40k
  • Dr. Michael Secora Ph.D. (Age 41)
    Chief Financial Officer
    Comp: $524.19k
  • Kevin Leggat
    Vice President of Finance & Accounting
  • Mr. Benjamin Mabey M.S. (Age 41)
    Chief Technology Officer
  • Mr. Jared Allenbach
    Senior Director of Investor Relations
  • Mr. Nathan Hatfield
    Chief Legal Officer & General Counsel
  • Mr. Ryan Kelly
    Chief Communications Officer
  • Mr. Matthew Kinn
    Chief Corporate Development Officer and SVP of Business Development & Corporate Initiatives

RXRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Recursion Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Recursion Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" RXRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RXRX, but not buy additional shares or sell existing shares.
View RXRX analyst ratings
or view top-rated stocks.

What is Recursion Pharmaceuticals' stock price target for 2024?

5 equities research analysts have issued 12 month price targets for Recursion Pharmaceuticals' stock. Their RXRX share price targets range from $8.00 to $17.00. On average, they anticipate the company's share price to reach $12.75 in the next twelve months. This suggests a possible upside of 72.3% from the stock's current price.
View analysts price targets for RXRX
or view top-rated stocks among Wall Street analysts.

How have RXRX shares performed in 2024?

Recursion Pharmaceuticals' stock was trading at $9.86 on January 1st, 2024. Since then, RXRX stock has decreased by 24.9% and is now trading at $7.40.
View the best growth stocks for 2024 here
.

When is Recursion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our RXRX earnings forecast
.

How were Recursion Pharmaceuticals' earnings last quarter?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) issued its earnings results on Tuesday, February, 27th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.06. The firm earned $10.89 million during the quarter, compared to analyst estimates of $12.37 million. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative trailing twelve-month return on equity of 72.88%.

What ETFs hold Recursion Pharmaceuticals' stock?
When did Recursion Pharmaceuticals IPO?

Recursion Pharmaceuticals (RXRX) raised $306 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 18,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO.

Who are Recursion Pharmaceuticals' major shareholders?

Recursion Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Green Alpha Advisors LLC (0.03%), TB Alternative Assets Ltd. (0.03%), Wedmont Private Capital (0.01%) and Oxinas Partners Wealth Management LLC (0.01%). Insiders that own company stock include Blake Borgeson, Christopher Gibson, Dean Y Li, Michael Secora, Mubadala Investment Co Pjsc, Shafique Virani, Terry-Ann Burrell, Tina Marriott, Tina Marriott Larson and Zavain Dar.
View institutional ownership trends
.

How do I buy shares of Recursion Pharmaceuticals?

Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RXRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners